Amended Statement of Beneficial Ownership (sc 13d/a)
September 24 2018 - 8:27AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of
1934
(Amendment No. 2)*
China Biologic Products Holdings, Inc.
(Name of Issuer)
Ordinary Shares, Par Value $0.0001
(Title of Class of Securities)
G21515104
(CUSIP Number)
Jiang Liwei
PW Medtech Group Limited
1002–1003, Block C, Focus Square
No. 6 Futong East Avenue
Wangjing, Chaoyang District, Beijing
People’s Republic of China
+86 10 8478 3617
(Name, Address and Telephone Number of
Person Authorized to Receive Notices and Communications)
September 21,
2018
(Date of Event which Requires Filing
of this Statement)
If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e),
1(f) or 1(g), check the following box.
¨
Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act
of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
|
|
|
|
|
|
1.
|
|
Names of Reporting Persons.
PW Medtech Group Limited
|
2.
|
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a)
¨
(b)
¨
|
3.
|
|
SEC Use Only
|
4.
|
|
Source of Funds (See Instructions)
BK
|
5.
|
|
Check if Disclosure of Legal Proceedings Is Required Pursuant
to Items 2(d) or 2(e)
¨
|
6.
|
|
Citizenship or Place of Organization
Cayman Islands
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
7.
|
|
Sole Voting Power
0
|
|
8.
|
|
Shared Voting Power
6,321,000 ordinary shares
|
|
9.
|
|
Sole Dispositive Power
0
|
|
10.
|
|
Shared Dispositive Power
6,321,000 ordinary shares
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
6,321,000 ordinary shares
|
12.
|
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)
¨
|
13.
|
|
Percent of Class Represented by Amount in Row (11)
16.08%
(1)
|
14.
|
|
Type of Reporting Person (See Instructions)
CO
|
|
|
|
|
|
|
|
|
(1) Percentage calculated based on 39,315,291
Ordinary Shares issued and outstanding as of September 21, 2018 as provided in the Issuer’s Form 6-Ks filed on August
27, 2018, September 4, 2018 and September 21, 2018.
|
|
|
|
|
|
|
1.
|
|
Names of Reporting Persons.
Cross Mark Limited
|
2.
|
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a)
¨
(b)
¨
|
3.
|
|
SEC Use Only
|
4.
|
|
Source of Funds (See Instructions)
OO
|
5.
|
|
Check if Disclosure of Legal Proceedings Is Required Pursuant
to Items 2(d) or 2(e)
¨
|
6.
|
|
Citizenship or Place of Organization
British Virgin Islands
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
7.
|
|
Sole Voting Power
0
|
|
8.
|
|
Shared Voting Power
2,204,133 ordinary shares
|
|
9.
|
|
Sole Dispositive Power
0
|
|
10.
|
|
Shared Dispositive Power
2,204,133 ordinary shares
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,204,133 ordinary shares
|
12.
|
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)
¨
|
13.
|
|
Percent of Class Represented by Amount in Row (11)
5.61%
(1)
|
14.
|
|
Type of Reporting Person (See Instructions)
CO
|
|
|
|
|
|
|
|
|
(1) Percentage calculated based on 39,315,291
Ordinary Shares issued and outstanding as of September 21, 2018 as provided in the Issuer’s Form 6-Ks filed on August
27, 2018, September 4, 2018 and September 21, 2018.
|
|
|
|
|
|
|
1.
|
|
Names of Reporting Persons.
Liu Yufeng
|
2.
|
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a)
¨
(b)
¨
|
3.
|
|
SEC Use Only
|
4.
|
|
Source of Funds (See Instructions)
OO
|
5.
|
|
Check if Disclosure of Legal Proceedings Is Required Pursuant
to Items 2(d) or 2(e)
¨
|
6.
|
|
Citizenship or Place of Organization
New Zealand
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With
|
|
7.
|
|
Sole Voting Power
0
|
|
8.
|
|
Shared Voting Power
2,204,133 ordinary shares
|
|
9.
|
|
Sole Dispositive Power
0
|
|
10.
|
|
Shared Dispositive Power
2,204,133 ordinary shares
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,204,133 ordinary shares
|
12.
|
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)
¨
|
13.
|
|
Percent of Class Represented by Amount in Row (11)
5.61%
(1)
|
14.
|
|
Type of Reporting Person (See Instructions)
IN
|
|
|
|
|
|
|
|
|
(1) Percentage calculated based on 39,315,291
Ordinary Shares issued and outstanding as of September 21, 2018 as provided in the Issuer’s Form 6-Ks filed on August
27, 2018, September 4, 2018 and September 21, 2018.
Introduction
This Amendment No.2 to Schedule 13D (this
“
Amendment No.2
”) amends and supplements the statement on Schedule 13D filed with the U.S. Securities and Exchange
Commission (the “
Commission
”) on January 10, 2018 (the “
Original Schedule 13D
” and the Schedule
13D/A filed on August 24, 2018, as amended and supplemented by this Amendment No.2, the “
Schedule 13D
”) by each
of PW Medtech Group Limited, Cross Mark Limited, and Ms. Liu Yufeng (the “
Reporting Persons
”) and relates to
the ordinary shares, par value $0.0001 per share (the “
Ordinary Shares
”) of China Biologic Products Holdings,
Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “
Issuer
”).
This Amendment No.2 is being filed to report
the completion of the transactions as contemplated under the Share Purchase Agreement and a margin loan agreement dated September
20, 2018 (the “
Margin Loan Agreement
”), entered into between PWM, Morgan Stanley Bank, N.A. and Morgan Stanley
& Co. International plc.
Except as provided herein, this Amendment
No.2 does not modify any of the information previously reported on the Original Schedule 13D, as amended. Capitalized terms used
but not defined in this Amendment No.2 have the means ascribed to them in the Original Schedule 13D, as amended.
Item 3. Source and Amount of Funds or Other
Consideration.
Item 3 of the Schedule 13D is hereby supplemented
by inserting the following after the last paragraph thereof:
On September 20, 2018, PWM entered
into the Margin Loan Agreement with Morgan Stanley Bank, N.A. as the lender (the “
Lender
”) and Morgan
Stanley & Co. International plc as the calculation agent (the “
Agent
”), pursuant to which the Lender
agreed to make a loan to PWM in an amount of US$82,720,000,for the purpose of obtaining the funds used to acquire the
Additional CBPO Shares under the Share Purchase Agreement. On September 20, 2018, PWM drew down an amount of US$82,720,000
under the Margin Loan Agreement to finance the acquisition of the Additional CBPO Shares.
To secure the loan under the Margin Loan
Agreement, on September 20, 2018, PWM as the chargor, and the Agent as the security agent entered into the debenture (the “
Debenture
”),
pursuant to which PWM charges, among others, 3,162,854 CBPO Shares in favour of the Agent as continuing security for the full
payment and discharge of its obligations under the Margin Loan Agreements.
Item 6. Contracts, Arrangements, Understandings
or Relationships with Respect to the Securities of Issuer.
Item 6 of the Schedule 13D is hereby amended
and supplemented by inserting the following paragraph before the last paragraph thereof:
Margin Loan Agreement
On September 20, 2018, PWM, the Lender
and the Agent entered into the Margin Loan Agreement, pursuant to which the Lender agreed to make a loan to PWM in an amount of
US$82,720,000.
Debenture
On September 20, 2018, PWM as the chargor,
and the Agent as the security agent entered into the Debenture, pursuant to which PWM charges, among others, 3,162,854 CBPO Shares
in favour of the Agent as continuing security for the full payment and discharge of its obligations under the Margin Loan Agreements.
Item 7. Materials to be Filed as Exhibits.
Item 7 of the Schedule 13D is hereby amended
and restated in its entirety as follows:
Exhibit 1
|
|
Joint Filing Agreement dated January 10, 2018 by the Reporting Persons (incorporated by reference to Exhibit 1 of the Original Schedule 13D filed by the Reporting Persons on January 10, 2018)
|
|
|
|
Exhibit 2
|
|
Share Exchange Agreement by and between the Issuer and PWM dated October 12, 2017 (incorporated by reference to Exhibit 99.2 to the Form 6-K filed with the U.S. Securities and Exchange Commission by the Issuer on October 13, 2017)
|
|
|
|
Exhibit 3
|
|
Amendment No. 1 to the Share Exchange Agreement, dated as of December 29, 2017, by and between the Issuer and PWM (incorporated by reference to Exhibit 99.1 to the Form 6-K filed with the U.S. Securities and Exchange Commission by the Issuer on December 29, 2017)
|
|
|
|
Exhibit 4
|
|
Investor Rights Agreement by and between the Issuer and PWM dated January 1, 2018 (incorporated by reference to Exhibit 99.2 to the Form 6-K filed with the U.S. Securities and Exchange Commission by the Issuer on January 3, 2018)
|
|
|
|
Exhibit 5
|
|
Share Purchase Agreement by and between the Issuer and PWM dated August 24, 2018 (incorporated by reference to Exhibit 99.4 to the Form 6-K filed with the U.S. Securities and Exchange Commission by the Issuer on August 27, 2018)
|
|
|
|
Exhibit 6*
|
|
Margin Loan Agreement by and
between PWM, Morgan Stanley Bank, N.A. and Morgan Stanley & Co. International plc dated September 20, 2018
|
*Filed herewith
SIGNATURES
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: September 24, 2018
|
PW MEDTECH GROUP LIMITED
|
|
|
|
|
By:
|
/s/ Jiang Liwei
|
|
|
Name:
|
Jiang Liwei
|
|
|
Title:
|
Executive Director and Chief Executive Officer
|
|
CROSS MARK LIMITED
|
|
|
|
|
By
|
/s/ Liu Yufeng
|
|
|
Name:
|
Liu Yufeng
|
|
|
Title:
|
Director
|
|
LIU YUFENG
|
|
|
|
|
By
|
/s/ Liu Yufeng
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024